Usana Health Sciences, Inc., a Utah-based nutritional, skincare and dietary products manufacturer, indicates in its recently filed 8-K that it has substantially completed an internal investigation into whether the expense reimbursement policy and other practices at its Chinese affiliate, BabyCare Ltd., were compliant with the Foreign Corrupt Practices Act. The company reports that it is cooperating with the DOJ and the SEC in their investigations of the matter.
February 5, 2019
DOJ and SEC investigating nutritional supplement maker for possible FCPA violations
Related by Topic
New Post
Florida judge sentences reinsurance manager to 10 months’ time served for role in Ecuadorian bribery scheme
July 2, 2025
News Alert
New Post
Rising Cross-Border Enforcement Risk for Companies Operating in Latin America
June 26, 2025
Insight